Ibis Kamuran, Saglam Sezer, Saglam Esra Kaytan, Firat Pinar, Yilmazbayhan Dilek, Toker Alper, Ozkan Berker, Hancer Veysel S, Buyukdogan Murat, Disci Rian, Pilanci Kezban Nur
Department of Radiation Oncology, Istanbul University Medical Faculty, Istanbul, Turkey.
Department of Medical Oncology, Istanbul Bilim University, Istanbul, Turkey.
Pathol Res Pract. 2018 Sep;214(9):1291-1296. doi: 10.1016/j.prp.2018.07.010. Epub 2018 Jul 11.
To assess the prognostic importance of carbonic anhydrase IX (CA IX), a hypoxic biomarker, after neoadjuvant treatment in Stage III non-small cell lung cancer (NSCLC) patients.
Tissue CA IX expression was examined after surgical resection in 77 patients who had undergone neoadjuvant treatment. The effects of CA IX overexpression and other clinical factors on disease-free survival and overall survival were investigated.
In multivariate analysis, number of neoadjuvant chemotherapy (CT) courses and gender emerged as significant independent predictors for disease-free survival, where administration of 2-3 courses of neoadjuvant chemotherapy (CT) (HR, 3.2 [95% CI 1.3-7.6], p = 0.009) and female gender were associated with poor survival (HR, 3.2 [95% CI 1.3-7.7], p = 0.009). The only significant independent predictor for overall survival was recurrence (HR, 5.6 [95% CI 2.4-12.8], p < 0.001). On the other hand, CA IX overexpression was not associated with disease free survival (p = 0.560) or overall survival (p = 0.799).
Our results do not suggest a prognostic role for CA IX overexpression in stage III NSCLC patients who received neoadjuvant treatment.
评估碳酸酐酶IX（CA IX）这一缺氧生物标志物在III期非小细胞肺癌（NSCLC）患者新辅助治疗后的预后重要性。
对77例接受新辅助治疗的患者手术切除后的组织CA IX表达进行检测。研究CA IX过表达及其他临床因素对无病生存期和总生存期的影响。
多因素分析显示，新辅助化疗（CT）疗程数和性别是无病生存期的显著独立预测因素，其中接受2 - 3个疗程新辅助化疗（CT）（风险比[HR]，3.2[95%置信区间1.3 - 7.6]，p = 0.009）和女性与较差的生存期相关（HR，3.2[95%置信区间1.3 - 7.7]，p = 0.009）。总生存期的唯一显著独立预测因素是复发（HR，5.6[95%置信区间2.4 - 12.8]，p < 0.001）。另一方面，CA IX过表达与无病生存期（p = 0.560）或总生存期（p = 0.799）无关。
我们的结果并不表明CA IX过表达在接受新辅助治疗的III期NSCLC患者中具有预后作用。
